VERIFIEDMint Markets·4 Aug 2026neutral

Sun Pharma’s premium push cushions US generics pain in Q1, but valuations look full

AI Summary

·Sun Pharma's India formulations and innovative medicines drove growth in Q1FY27.
·Management reiterated the company's FY27 guidance.
·Margins are expected to face near-term pressure due to investments and the Organon acquisition.